Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ispinesib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-14 of 14 for your search:
Start Over
A Study of Ispinesib in Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CY 3121, NCT00607841
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KSP20007, NCT00085813
Study Of Ispinesib In Subjects With Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KSP20001, NCT00089973
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02630, SWOG-S0418, U10CA032102, CDR0000393206, S0418, NCT00096499
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03091, PHL-031, 6803, N01CM62203, PMH-PHL-031, NCI-6803, NCT00095628
Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KSP20008, NCT00097409
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2012-02928, 14577A, N01CM62201, CCUM-14577A, 7673, NCI-7673, NCT00354250
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I169, CAN-NCIC-IND169, CDR0000391842, NCIC-169, IND169, NCT00095953
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I168, CAN-NCIC-IND168, CDR0000391839, NCIC-168, IND168, NCT00095992
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02834, PHII-51, 6800, CCC-PHII-51, NCI-6800, NCT00103311
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03127, CASE 3904, U01CA062502, U01CA062505, CASE-CWRU-3904, NCI-6777, 6777, CWRU-070418, NCT00098826
Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KSP10004, NCT00119171
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KSP10014, NCT00136578
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2012-01828, ADVL0517, U01CA097452, CDR0000491407, COG-ADVL0517, NCT00363272
Start Over